Author:
Lasalvia-Prisco Eduardo,Goldschmidt Pablo,Galmarini Felipe,Cucchi Silvia,Vázquez Jesús,Aghazarian Martha,Lasalvia-Galante Eduardo,Golomar Wilson,Gordon William
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference36 articles.
1. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118:1991–2001.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.
3. Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics. 2008;2(1):53–9.
4. Lasalvia-Prisco E, Goldschmidt P, Galmarini F, et al. Switch of biological response (angiogenesis and immunity) as target of complementary treatments in malignancy. In: 37th ESMO congress, Vienna 2012, 28 Sept–02 Oct 2012. Accepted.
5. Miller K, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19:1195–206.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献